Rubric v1
How we rank GLP-1 options
Scores are editorial judgments made from public sources. They are not medical advice, and they are not for sale.
The 100-point rubric
| Criterion | Weight | What we look at |
|---|---|---|
| Evidence and label fit | 25 | FDA indication match, and the quality of pivotal trials cited from PubMed or the label. |
| Price transparency | 20 | A published cash or self-pay price, what “month” means, and a dated source. |
| Total cost realism | 15 | Membership, labs, medicine, and shipping. Unknowns are disclosed, not smoothed over. |
| Care quality signals | 15 | Licensed clinicians, follow-up, and whether state coverage is disclosed. |
| Safety and product authenticity | 15 | A path to an FDA-approved product, pharmacy licensing, and no gray-market detour. |
| UX and support | 10 | Intake clarity, cancellation terms, and cold-chain claims a reader can check. |
The same weights apply to a drug ranking and to a telehealth scorecard. A drug is not graded on bedside manner, and a clinic is not graded as if it ran the pivotal trial. Where a criterion does not fit, we say so and we do not quietly reassign the points.
Sourcing rules
- Prices come from manufacturer list-price pages, manufacturer self-pay or savings terms, or an archived provider page with a capture date.
- Every figure is labeled manufacturer-reported, provider-reported, orindependently verified.
- Clinical claims cite FDA labels and peer-reviewed primary publications. We summarize. We do not republish a label or a paper.
- Quotes stay short and attributed.
Freshness
- Prices: rechecked within 30 days, or the page says the figure is older.
- Regulatory status: rechecked within 90 days.
- Clinical citations: rechecked within 180 days, or the page notes the label revision date.
Hard bans
- No ranking of, and no affiliate link to, illegal compounded sellers, research-peptide shops, or overseas gray-market sources.
- No dosing advice written for a specific reader, and no “start this drug” instruction.
- No implied equivalence between a compounded product and an FDA-approved drug. TheFDA’s page on unapproved GLP-1 drugs used for weight lossis the reference we send readers to.
Conflicts
A commercial relationship is disclosed on the page. If we cannot confirm whether one exists, we say “unconfirmed.” Display ads, if a network is added later, stay in labeled slots and do not buy placement inside a score. See the affiliate disclosure.
Corrections go to the contact page. A wrong price should be replaced, not defended.